Champions Oncology
CSBR
30 hedge funds and large institutions have $23.6M invested in Champions Oncology in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
3% more funds holding
Funds holding: 29 → 30 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.05% less ownership
Funds ownership: 44.28% → 43.22% (-1.1%)
11% less capital invested
Capital invested by funds: $26.5M → $23.6M (-$2.97M)
50% less call options, than puts
Call options by funds: $33K | Put options by funds: $66K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
+$215K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$110K |
| 3 |
Stifel Financial
St. Louis,
Missouri
|
+$95.4K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.49K |
| 5 |
Morgan Stanley
New York
|
+$5.15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAG
Millrace Asset Group
Berwyn,
Pennsylvania
|
-$875K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$109K |
| 3 |
Renaissance Technologies
New York
|
-$31.6K |
| 4 |
BlackRock
New York
|
-$26.5K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$23.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $10K | +$2.98K | +698 | +36% |
|
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $7K | +$6.49K | +1,518 | +1,026% |
|
|
SFG
28
Steward Financial Group
Colleyville,
Texas
| $3K | – | – | – |
|
29
Wells Fargo
San Francisco,
California
| $173 | +$4 | +1 | +2% |
|
|
MAG
30
Millrace Asset Group
Berwyn,
Pennsylvania
| – | -$875K | -194,010 | Closed |
|
CSBR Hedge Fund Activity: Q1 2023 in Review
30 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q1 2023, worth a combined $23.6M — down 11% from $26.5M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new CSBR positions and 1 closed out — a net gain of 1 holder — while 8 added to existing stakes and 6 trimmed.
The largest buyer was Tocqueville Asset Management, adding an estimated $215K. The largest seller was Millrace Asset Group, exiting entirely with an estimated $875K sold.
- 30 institutional investors held Champions Oncology (CSBR) as of Q1 2023, up from 29 in Q4 2022.
- Funds reported $23.6M of Champions Oncology stock for Q1 2023, down 11% quarter-over-quarter.
- 2 funds opened new Champions Oncology positions in Q1 2023 and 1 closed out, a net change of +1 holder.
- The largest Champions Oncology buyer in Q1 2023 was Tocqueville Asset Management, an estimated $215K added.
- The largest Champions Oncology seller in Q1 2023 was Millrace Asset Group, an estimated $875K sold.
Based on aggregated 13F filings for Q1 2023.